B1N0 Stock Overview
A clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bionomics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.25 |
| 52 Week High | US$1.45 |
| 52 Week Low | US$0.15 |
| Beta | -0.069 |
| 11 Month Change | -7.35% |
| 3 Month Change | n/a |
| 1 Year Change | -85.92% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| B1N0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.8% | -0.7% | -0.02% |
| 1Y | -85.9% | -17.2% | 8.2% |
Return vs Industry: B1N0 underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: B1N0 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| B1N0 volatility | |
|---|---|
| B1N0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine B1N0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 16 | Spyros Papapetropoulos | www.bionomics.com.au |
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Bionomics Limited Fundamentals Summary
| B1N0 fundamental statistics | |
|---|---|
| Market cap | €4.62m |
| Earnings (TTM) | -€10.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs B1N0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| B1N0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.82m |
| Earnings | -US$10.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.62 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did B1N0 perform over the long term?
See historical performance and comparison